{"product_id":"simlukafusp-alfa-elisa-kit-bhe21400256","title":"Simlukafusp Alfa ELISA Kit","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eSimlukafusp Alfa ELISA Kit\u003c\/strong\u003e is an ELISA-based immunoassay designed for quantitative measurement of \u003cstrong\u003eSimlukafusp Alfa\u003c\/strong\u003e in research samples. It is commonly used to generate traceable concentration data for biomarker discovery, pathway studies, and comparative analyses across experimental conditions.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay format:\u003c\/strong\u003e Quantitative Colorimetric ELISA. The format defines how signal scales with analyte abundance and how results are interpreted across a standard curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorking range and sensitivity:\u003c\/strong\u003e dynamic range 0.31-5 μg\/mL; analytical sensitivity 0.156 μg\/ml. Use these values to plan dilutions and keep readouts within the linear portion of the calibration curve.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSample compatibility:\u003c\/strong\u003e Intended for Plasma, Serum matrices. As with most immunoassays, matrix composition can influence apparent signal and should be evaluated with dilution linearity and spike-recovery concepts.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRecovery reference:\u003c\/strong\u003e Typical recovery is reported as 80-120%. Recovery helps assess whether the sample matrix interferes with detection of spiked analyte.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThis kit is supplied for research use in laboratory settings where defined, quantitative readouts are needed for experimental interpretation.\u003c\/p\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eSimlukafusp alfa (FAP-IL2v, RO6874281\/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein 伪 (FAP) and an IL-2 variant with a retained affinity for IL-2R尾纬 \u0026gt; IL-2 R尾纬 and abolished binding to IL-2 R伪. Here, we investigated the immunostimulatory properties of FAP-IL2v and its combination with programmed cell death protein 1 (PD-1) checkpoint inhibition, CD40 agonism, T cell bispecific and antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. The binding and immunostimulatory properties of FAP-IL2v were investigated in vitro and compared with FAP-IL2wt. Tumor targeting was investigated in tumor-bearing mice and in a rhesus monkey. The ability of FAP-IL2v to potentiate the efficacy of different immunotherapies was investigated in different xenograft and syngeneic murine tumor models. FAP-IL2v bound IL-2 R尾纬 and FAP with high affinity in vitro, inducing dose-dependent proliferation of natural killer (NK) cells and CD4+\/CD8+ T cells while being significantly less potent than FAP-IL2wt in activating immunosuppressive regulatory T cells (Tregs). T cells activated by FAP-IL2v were less sensitive to Fas-mediated apoptosis than those activated by FAP-IL2wt. Imaging studies demonstrated improved tumor targeting of FAP-IL2v compared to FAP-IL2wt. Furthermore, FAP-IL2v significantly enhanced the in vitro and in vivo activity of therapeutic antibodies that mediate antibody-dependent or T cell-dependent cellular cytotoxicity (TDCC) and of programmed death-ligand 1 (PD-L1) checkpoint inhibition. The triple combination of FAP-IL2v with an anti-PD-L1 antibody and an agonistic CD40 antibody was most efficacious. These data indicate that FAP-IL2v is a potent immunocytokine that potentiates the efficacy of different T- and NK-cell-based cancer immunotherapies.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiomarker translation in RUO settings:\u003c\/strong\u003e Increasing use of quantitative immunoassays to stratify experimental cohorts, track longitudinal changes, and benchmark model systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix-aware assay design:\u003c\/strong\u003e Greater emphasis on dilution linearity, spike-recovery, and control concepts to reduce matrix-driven artifacts in serum\/plasma and complex lysates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIntegration with multi-omics:\u003c\/strong\u003e ELISA measurements are often used alongside transcriptomics and proteomics to connect abundance changes with pathway activity and phenotype.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComparative quantification:\u003c\/strong\u003e Measure relative changes in analyte levels across treatments, time points, or genotypes to support mechanistic hypotheses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAssay development and standardization:\u003c\/strong\u003e Generate reproducible concentration inputs for method qualification, inter-operator comparisons, or bridging studies across platforms.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eModel and sample characterization:\u003c\/strong\u003e Profile baseline and stimulated levels to help interpret immune, endocrine, neurodegenerative, or metabolic phenotypes (as relevant to the target).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on direction and magnitude of change in the context of controls and sample handling metadata, rather than single-point absolute values.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMatrix effects:\u003c\/strong\u003e Hemolysis, lipemia, and high protein content can alter background and apparent concentration. Consider consistent collection\/processing and evaluate dilution behavior.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsoforms and modified forms:\u003c\/strong\u003e Some targets exist as isoforms, fragments, or post-translationally modified species. Ensure the measured form aligns with the biological question and the kit’s intended analyte definition.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e Use negative\/blank controls, replicate wells, and—when feasible—orthogonal confirmation (e.g., WB or MS) to strengthen conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal): - UniProt (search): https:\/\/www.uniprot.org\/uniprotkb?query=Simlukafusp+Alfa - NCBI Gene (search): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=Simlukafusp+Alfa - Ensembl (search): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=Simlukafusp+Alfa - PubMed (search): https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Simlukafusp+Alfa - NCBI Bookshelf (background reviews): https:\/\/www.ncbi.nlm.nih.gov\/books\/?term=Simlukafusp+Alfa --\u003e","brand":"Biohippo Inc","offers":[{"title":"96 T","offer_id":53047351574893,"sku":"DC440028-96T","price":1126.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/ELISA_Kits_Display_Image_1_21ba0ec7-3db0-406e-ab01-679d05e44710.png?v=1772020759","url":"https:\/\/www.ebiohippo.com\/products\/simlukafusp-alfa-elisa-kit-bhe21400256","provider":"BioHippo","version":"1.0","type":"link"}